Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.55 |
| ▸ | KDM6B | O15054 | 1/20 | 0.55 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.55 |
| ▸ | CFD | P00746 | 1/20 | 0.54 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.52 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691864 | 0.86 | HSD17B10 (0.81) | KDM4EALDH1A1HSD17B10POLBHPGD | |
| SCHEMBL7081875 | 0.84 | ALDH1A1 (0.52) | KDM4EALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL28172078 | 0.80 | HSD17B10 (0.67) | KDM4EALDH1A1HSD17B10POLBHPGD | |
| SCHEMBL4730865 | 0.80 | CDC7 (0.65) | KDM4EALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL30491663 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL11674545 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL11509875 | 0.79 | MAPT (0.59) | KDM4EALDH1A1HSD17B10POLBHPGD | |
| SCHEMBL27327995 | 0.79 | HSD17B10 (0.65) | KDM4EALDH1A1HSD17B10POLBHPGD | |
| Phthalic Acid SCHEMBL29049255 | 0.78 | KMT2A (0.61) | KDM4EALDH1A1LMNAHSD17B10POLB | |
| SCHEMBL6720193 | 0.78 | KMT2A (0.77) | LMNAHPGDL3MBTL1CFDCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | claimed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | claimed |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-03-01 | — | — | US | claimed |
| US-10954258-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200199160-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20180179235-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-28 | — | — | US | disclosed |
| US-9822135-B2 | STAT3 dimerization inhibitors | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20150259366-A1 | STAT3 DIMERIZATION INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-17 | — | — | US | disclosed |
| WO-2014070859-A1 | STAT3 DIMERIZATION INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | disclosed |
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-06-11 | — | — | US | disclosed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | disclosed |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | KDM4E 3014/4885ALDH1A1 1961/4885LMNA 61/4885 |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | KDM4E 3014/4885ALDH1A1 1961/4885LMNA 61/4885 |
| US-20200199160-A1 | STAT3 DIMERIZATION INHIBITORS | STAT3, JAK2, STAT1 | KDM4E 3607/4885ALDH1A1 3098/4885LMNA 4070/4885 |
| US-20180179235-A1 | STAT3 DIMERIZATION INHIBITORS | STAT3, JAK2, STAT1 | KDM4E 3607/4885ALDH1A1 3098/4885LMNA 4070/4885 |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | BCL2, BAX, SMN1; SMN2 | KDM4E 3014/4885ALDH1A1 1961/4885LMNA 61/4885 |
| US-10954258-B2 | STAT3 dimerization inhibitors | STAT3, JAK2, STAT1 | KDM4E 3607/4885ALDH1A1 3098/4885LMNA 4070/4885 |
| US-20150259366-A1 | STAT3 DIMERIZATION INHIBITORS | STAT3, JAK2, STAT1 | KDM4E 3607/4885ALDH1A1 3098/4885LMNA 4070/4885 |
| US-20070049565-A1 | Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction | BAD, MAP1LC3B, XIAP | KDM4E 4124/4885ALDH1A1 2762/4885LMNA 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.